- Oral presentation
- Open Access
The ischaemic and scar burden measured by cardiac magnetic resonance imaging in patients with ischaemic coronary heart disease from the CE-MARC study
© Plein et al; licensee BioMed Central Ltd. 2013
- Published: 30 January 2013
- Coronary Heart Disease
- Single Photon Emission Compute Tomography
- Cardiac Magnetic Resonance
- Late Gadolinium Enhancement
- Cardiac Magnetic Resonance Imaging
The prognostic importance of the ischaemic and scar burden, and their impact on coronary heart disease (CHD) patient management is well established from single photon emission computed tomography (SPECT) studies. Recently, cardiac magnetic resonance (CMR) has been shown to have superior sensitivity for the detection of CHD compared with SPECT . However, the ischaemic and the scar burden measured by CMR and SPECT have not been compared.
From the prospective CE-MARC study, all patients who had significant coronary artery stenosis (≥70% of a first order coronary artery or ≥50% of the left main artery) on quantitative invasive coronary angiography and ischaemia on both CMR and SPECT were selected. The summed stress score (SSS), the summed rest score (SRS) as well as the summed difference score (SDS) were assessed based on a 5-point scoring scale (0=normal; 4=severe) for perfusion defects and/or late gadolinium enhancement (LGE) using a 16-segment model; comparisons were made between the two modalities. Bland-Altman limits of agreement (BA) were calculated.
CMR is an alternative to SPECT in identifying the presence of CHD. This subanalysis of CE-MARC shows that for the assessment of overall disease burden, the two tests are comparable. However, there is a discrepancy in the detection of ischaemia versus scar between the two methods and CMR measures significantly less scar but significantly more ischaemia than SPECT. Potential reasons for this discrepancy include the differences in the methodology for scar imaging (LGE vs. matched defect) and the difference in cardiac coverage for perfusion assessment. Further studies will have to show the impact of these findings on patient outcome.
The CE-MARC study was funded by a British Heart Foundation Programme Grant (RG/05/004). S.P is funded by British Heart Foundation fellowship (FS/10/62/28409).
- Wagner GA, et al: . J Cardiovasc Magn Resn. 2009Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.